Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. - Wikidata - wikimedia - TriplyDB

Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911.

Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911.

http://www.wikidata.org/entity/Q36945391

about

Adjuvant radiotherapy following radical prostatectomy for prostate cancer Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial The Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate Cancer Radiation Therapy after Radical Prostatectomy: Implications for Clinicians Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer Prostate cancer: ESMO Consensus Conference Guidelines 2012 Real-time, near-infrared fluorescence imaging with an optimized dye/light source/camera combination for surgical guidance of prostate cancer.Prognostic outlier genes for enhanced prostate cancer treatment.Emergency surgery in patients who have undergone recent radiotherapy is associated with increased complications and mortality: review of 536 patients.Postoperative systems models more accurately predict risk of significant disease progression than standard risk groups and a 10-year postoperative nomogram: potential impact on the receipt of adjuvant therapy after surgery.Counseling patients about sexual health when considering post-prostatectomy radiation treatment.Predicting 15-year prostate cancer specific mortality after radical prostatectomy.Identification of men with the highest risk of early disease recurrence after radical prostatectomy What are the outcomes of radical prostatectomy for high-risk prostate cancer?Long-term survival after radical prostatectomy for men with high Gleason sum in pathologic specimen.Positive surgical margins at radical prostatectomy predict prostate cancer specific mortality Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy.Tri-Modality therapy with I-125 brachytherapy, external beam radiation therapy, and short- or long-term hormone therapy for high-risk localized prostate cancer (TRIP): study protocol for a phase III, multicenter, randomized, controlled trial.Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer.Proposed salvage treatment strategy for biochemical failure after radical prostatectomy in patients with prostate cancer: a retrospective study.Saudi Oncology Society clinical management guidelines for prostate cancer.Radiotherapy after radical prostatectomy: treatment recommendations differ between urologists and radiation oncologists.A contemporary analysis of outcomes of adenocarcinoma of the prostate with seminal vesicle invasion (pT3b) after radical prostatectomy Evolution of the clinical presentation of men undergoing radical prostatectomy for high-risk prostate cancer.Postoperative radiotherapy after radical prostatectomy: indications and open questions The need for, and utilization of prostate-bed radiotherapy after radical prostatectomy for patients with prostate cancer in British Columbia.Fifth-generation digital immunoassay for prostate-specific antigen by single molecule array technology Tissue biomarkers for prostate cancer radiation therapy.Overall rate, location, and predictive factors for positive surgical margins after robot-assisted laparoscopic radical prostatectomy for high-risk prostate cancer.Adjuvant radiotherapy following radical prostatectomy: Genito-Urinary Radiation Oncologists of Canada Consensus Statement Is lymphovascular invasion a powerful predictor for biochemical recurrence in pT3 N0 prostate cancer? Results from the K-CaP database Use of androgen deprivation therapy as salvage treatment after primary therapy for clinically localized prostate cancer.Impact of surgical margin status on prostate-cancer-specific mortality.Physician beliefs and practices for adjuvant and salvage radiation therapy after prostatectomy.Additional therapy for high-risk prostate cancer treated with surgery: what is the evidence?Neoadjuvant therapy preceding prostatectomy for prostate cancer: rationale and current trials.Neoadjuvant radiotherapy for locally advanced and high-risk prostate cancer.High-risk prostate cancer: the role of radical prostatectomy for local therapy.Radiation therapy for prostate cancer after prostatectomy: adjuvant or salvage?High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy.

P2860

Q24234347-00DB178A-1C65-467B-90B4-278922DFA227 Q24605205-71E8571D-ED70-4DDC-BD48-6925460AD02B Q26738703-95BDEF67-4A43-443D-A095-BCDF578C926F Q26744531-263D4B35-327C-435C-9B1E-C3BE38B82A8F Q26747782-AD61F0CB-0168-4021-AA0F-D7DBD3709A9D Q27022847-A9812135-FC93-463D-A476-C04144C9E61C Q27346788-B1EB8866-1610-4533-A408-7451C773D2CB Q30244674-B582A8E8-A5EB-4E35-9418-0750EFF9702F Q33398240-BC931293-5205-4E2F-9269-D1BA77305402 Q33669456-7B14DD5B-5C2C-4AC8-AA36-10442BE0C168 Q33710312-79B087B5-DC88-4302-94D9-0C8F8486B990 Q33759725-44543433-8271-4093-ACC7-FF906ECC89BE Q33825388-0B577849-F1BF-4DCD-A146-B57FC1071AAC Q33927594-F85CD204-1F7E-4009-82FA-3C1379A8C526 Q33965472-8ADB3F81-CD1A-47A2-8889-3949B3691F08 Q33990394-1E0EE798-10D3-4C56-8835-E408C416FADE Q34013761-3D650FD8-6D0A-4B77-8640-010F08449ED5 Q34206798-B73F5E48-7BCB-4352-927B-1E0250ED5EFF Q34437308-942FD672-3FAB-46C0-8512-5CC77121006D Q34812281-EE5767E2-462E-45CC-B909-AE239D8BBC00 Q34997355-177BCCD9-FC34-49DF-B5A3-1170E011459D Q35041485-867D5164-2914-4640-ABA1-C8115065B57B Q35322697-E4187E63-1F9D-4EA5-A13D-83A94FC2DC5B Q35605945-7348115C-9DE9-4A7C-993A-E3FC3D77452D Q35863963-4493C1D1-DC0C-46DF-86DD-3641090631A0 Q35894629-4E097F6C-33B5-4B49-B170-90F63618D09B Q36108451-36F7666B-F868-4B52-9D4F-73EEDE73CBF9 Q36141341-C6A9170B-D90B-409E-9753-EBC3DE266F7F Q36530193-EF2B6B25-C5E4-4D68-B9E0-64D6994E00BF Q36710328-DF3FB4F5-2D78-406E-9AA7-AE875F5F2645 Q36870722-C2A9B6D2-F7CA-431D-BBEC-CF7A1E2D2177 Q37342222-EFC31540-D1FE-4C21-87EA-7B7C00038424 Q37421927-431CFF66-D4D0-4BC8-BC8D-63DEC9C706CA Q37427663-BDF6B0BD-FB92-4159-B94E-9AB4259E708C Q37546041-99C8E0E8-2C5A-4C42-AE5E-C28604475612 Q37705424-080279AD-8749-43C6-B271-06168761EAC3 Q37823204-FB36DF02-290E-434C-A877-A7061B8B710F Q37861198-25C7285B-E503-4B87-9982-33F6FA7C7271 Q37889109-EA79B7B0-8780-482E-910A-06478E4DB3EA Q37944906-8E359D36-992C-44EA-9526-3CFC7EB78519

P2860

Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911.

http://www.wikidata.org/entity/Q36945391

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Identification of patients wit ...... ive radiotherapy: EORTC 22911.

@en

type

label

Identification of patients wit ...... ive radiotherapy: EORTC 22911.

@en

prefLabel

Identification of patients wit ...... ive radiotherapy: EORTC 22911.

@en

P1433

Q36945391-8DB2AEFC-9E06-4240-AC3C-2B4E86142926

P1476

Q36945391-94293ECB-A027-472E-AF34-518E02500091

P2093

Q36945391-1A130BC1-5A23-4F24-9D1F-AE70693DDB51

Q36945391-26A5EE0D-8B4F-44B6-90F2-BC26D8DAABBA

Q36945391-7697B70A-A9AA-4565-B1B8-18A10C777BA2

Q36945391-8914FC0C-831F-4250-B61E-D525A104081D

Q36945391-903E28FF-28D1-42D2-B3E8-14CF3EE436DB

Q36945391-9EE97895-F018-4A0A-BC40-079C1EE3EC4B

Q36945391-CB4D1C40-F730-4DB8-BCF5-32F0640E450B

Q36945391-D346A620-3DE0-46D0-AF38-4C031753670C

Q36945391-E4A492FF-1085-46CE-8F68-DA21626AA137

Q36945391-F5279E2E-C3B5-4DD3-84D2-E746F4CC6684

P304

Q36945391-10DA21C2-9132-4A8C-961B-E711EAB45806

P31

Q36945391-1BD49F56-7422-4529-B076-7610D0BBF84C

P356

Q36945391-DE87D20F-819B-4F24-AB7F-4A56F815BF73

P407

Q36945391-C192F05B-F611-4E2F-A462-85D651C43B0F

P433

Q36945391-CCAFE9CA-DA24-4184-83C6-CC63459C7342

P478

Q36945391-7FBCAFAD-1D7F-4E5B-BF8D-F4A168887170

P50

Q36945391-4785634F-C97F-4C4E-8D18-35E4CD7E9AD4

P577

Q36945391-29AC1184-6709-4F28-9E50-237D2583AF33

P698

Q36945391-6401FC6E-A6FF-4F53-92D5-5B91CB5E8EC7

P921

Q36945391-D048A105-D0D2-4A3F-A9A7-4F31B053AC9B

P356

JCO.2006.10.4067

P1433

Journal of Clinical Oncology

P1476

Identification of patients wit ...... ive radiotherapy: EORTC 22911.

@en

P2093

EORTC 22911

http://www.w3.org/2001/XMLSchema#string

Fritz H Schröder

http://www.w3.org/2001/XMLSchema#string

Hein Van Poppel

http://www.w3.org/2001/XMLSchema#string

Jean-Francois Bosset

http://www.w3.org/2001/XMLSchema#string

Karl H Kurth

http://www.w3.org/2001/XMLSchema#string

Kris Vekemans

http://www.w3.org/2001/XMLSchema#string

Laurence Collette

http://www.w3.org/2001/XMLSchema#string

Luigi Da Pozzo

http://www.w3.org/2001/XMLSchema#string

Michel Bolla

http://www.w3.org/2001/XMLSchema#string

Paul Van Cangh

http://www.w3.org/2001/XMLSchema#string

P304

4178-4186

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2006.10.4067

http://www.w3.org/2001/XMLSchema#string

P407

P433

27

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P50

Theodorus H Van der Kwast

P577

2007-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17878474

http://www.w3.org/2001/XMLSchema#string

P921

radiation therapy